PNC-27

PNC-27 is a lab-made peptide studied experimentally as a cancer-cell killer. In laboratory studies, it binds a protein called HDM-2 found on cancer-cell membranes and pokes holes in that membrane, killing the cancer cell while reportedly sparing normal cells. It's built from a piece of the p53 tumor-suppressor protein joined to a short 'membrane-penetrating' sequence. All of this evidence is in cell cultures and animals, with no human trials, and it is not FDA-approved and is not a cancer treatment.

PNC-27 has been studied as an experimental anticancer peptide, and its evidence is entirely preclinical. It was reported to kill breast-cancer cells while sparing normal breast cells by forming pores in the cancer-cell membrane, and to kill a leukemia cell line in a way that depended on a specific protein (HDM-2) in the cancer-cell membrane. These are cell-culture and animal findings only — there are no human trials, and nothing here indicates PNC-27 is safe or effective in people.

Not FDA-approved for any indication. Investigational; evidence is entirely preclinical (cancer cell lines and animal models) — there are no human trials of PNC-27. It is not a cancer treatment and must not be used as one. WADA status: not specifically named on the Prohibited List; as a non-approved research peptide it is best treated as captured under S0 (non-approved substances), prohibited at all times in regulated sport — verify with your anti-doping organization. Not DEA-scheduled.

PNC-27 has no human data of any kind and is not a cancer treatment. Anyone facing cancer should work with an oncologist and evidence-based care — an unproven research peptide is not a substitute and could be dangerous or delay real treatment. PNC-27 is not FDA-approved. As a non-approved research peptide it is best treated as prohibited in regulated sport at all times under the WADA S0 category. VialWise is a research and educational reference, not medical advice.

⚠️ For research and educational purposes only — PNC-27 is not a cancer treatment. PNC-27 is not approved by the FDA for any indication. Its entire evidence base is preclinical (cancer cell lines and animals) — there are no human trials. Nothing in this entry should be read as suggesting PNC-27 can treat, cure, or manage cancer in people. Anyone facing cancer should work with a qualified oncologist and evidence-based care. Using an unproven compound in place of real treatment can be dangerous and can delay effective care.

⚠️ All evidence is preclinical, from one research group. Every finding below comes from cell-culture and animal studies, primarily from the SUNY Downstate / Drexel laboratories.[¹][²][³] Anticancer peptides with promising cell data very often fail in humans. There is no human dose, safety, or efficacy data for PNC-27.

⚠️ This entry describes a mechanism, not a therapy. The selectivity and cell-killing described are laboratory observations. They are included for completeness because PNC-27 is sold as a research peptide — not as an endorsement or a protocol.

PNC-27 is a synthetic, membrane-active anticancer peptide designed around a targeting idea from the p53 tumor-suppressor protein. It joins a p53-derived sequence (the region that binds HDM-2, also called MDM2 — the protein that normally regulates p53) to a membrane-penetrating sequence. The originating laboratories (SUNY Downstate Medical Center and Drexel University College of Medicine) proposed that PNC-27 works not by restoring p53 signaling but by a direct membrane mechanism.[¹][²][³]

Proposed mechanism (as described in preclinical work). According to PubMed: - PNC-27 is reported to bind HDM-2 that is expressed in the plasma membrane of cancer cells (but not, the group argues, in normal cells), and to co-localize with membrane HDM-2 as an early event, leading to transmembrane pore formation and tumor-cell necrosis — a mechanism said to be independent of p53 activity in the target cell.[¹] - In a p53-null leukemia line (K562), PNC-27 induced near-complete cell killing with lactate-dehydrogenase (LDH) release (a necrosis marker) while sparing control leukocytes, and this depended on HDM-2 being present in the cell membrane — extending the mechanism from solid tumors to a non-solid (leukemia) line.[¹] - Using a double-fluorescent-labeled PNC-27, the peptide was shown to act as the intact molecule (not fragments) in the membrane of MCF-7 breast cancer cells, killing them, while untransformed MCF-10-2A breast cells remained viable (the peptide was taken up uniformly then degraded without killing them).[²] - Work on the closely related PNC-28 in pancreatic cancer cells (MiaPaCa-2) showed that the penetratin (membrane-penetrating) sequence is responsible for switching the mechanism to rapid necrosis via membrane pore formation — without it, cell death occurred by apoptosis instead.[³]

The selectivity claim. The central and most-cited claim is selective toxicity to cancer cells over normal cells, attributed to HDM-2 being present in the cancer-cell membrane specifically. This is an interesting hypothesis supported by the group's cell-culture and animal data, but it has not been established in humans, and the entire body of evidence comes largely from one set of collaborating laboratories.

Evidence quality. PNC-27's evidence is entirely preclinical — cancer cell lines and animal models — and concentrated in a single research program. There are no human clinical trials. Anticancer agents that kill cells selectively in a dish routinely fail to show benefit (or prove unsafe) in people. PNC-27 should be understood as a research-stage mechanism, not a therapy.

Regulatory status (US). PNC-27 is not FDA-approved and is not DEA-scheduled. It is available only as a research-supply peptide outside the FDA-recognized supply chain.

Regulatory status (sport — WADA). PNC-27 is not specifically named on the WADA Prohibited List (it is not a performance-relevant compound). As a non-approved research peptide it is nonetheless best treated as captured under S0 (non-approved substances), prohibited at all times. Verify current status via the WADA Prohibited List and your National Anti-Doping Organization.

Common research interests. Selective cancer-cell killing via a membrane HDM-2 mechanism, studied across breast, leukemia, pancreatic, and other cell models. These are laboratory research interests, not human uses, and PNC-27 is not a treatment for any condition.

Commonly reported

• Unknown human tolerability and toxicity — no human has been studied; a membrane-active peptide has unknown effects on normal tissues in vivo
• Immune / infusion reactions — a general concern for parenteral peptides
• Research-supply purity — variable quality of non-pharmaceutical material is a general risk
• The greatest risk is misuse as a cancer treatment — see warnings

Not a cancer treatment — PNC-27 must not be used to treat, replace, or delay evidence-based cancer care. Anyone with cancer should work with an oncologist.

Pregnancy and lactation — no data; default to contraindicated

Pediatric use — no data; should not be used in researchers under 18

Known hypersensitivity — contraindicated

Regulatory note (US): Not FDA-approved; available only as research-supply material outside the FDA-recognized supply chain. Not DEA-scheduled.

Regulatory note (sport): Not specifically named on the WADA Prohibited List, but best treated as S0 (non-approved substances), prohibited at all times. Verify with your anti-doping organization.

p53

A tumor-suppressor protein that helps prevent cancer. PNC-27 uses a small piece of p53 as its targeting sequence.

HDM-2 (MDM2)

A protein that normally regulates p53. PNC-27 binds HDM-2 that is present in cancer-cell membranes, which is proposed to explain its selectivity.

Membrane-penetrating peptide

A short sequence that helps a peptide cross or disrupt cell membranes. PNC-27 carries one to reach and puncture the cancer-cell membrane.

Necrosis

A form of cell death by membrane rupture (as opposed to the orderly, programmed death called apoptosis). PNC-27 is reported to kill cancer cells by necrosis.

Preclinical

Research in cells or animals, before any human testing. Preclinical anticancer results very often do not translate to people.

1. Davitt K, Babcock BD, Fenelus M, Poon CK, Sarkar A, Trivigno V, Zolkind PA, Matthew SM, Grin'kina N, Orynbayeva Z, Shaikh MF, Adler V, Michl J, Sarafraz-Yazdi E, Pincus MR, Bowne WB. (2014). The anti-cancer peptide, PNC-27, induces tumor cell necrosis of a poorly differentiated non-solid tissue human leukemia cell line that depends on expression of HDM-2 in the plasma membrane of these cells. Annals of Clinical and Laboratory Science, 44(3):241–248.(PMID 25117093)
2. Sookraj KA, Bowne WB, Adler V, Sarafraz-Yazdi E, Michl J, Pincus MR. (2010). The anti-cancer peptide, PNC-27, induces tumor cell lysis as the intact peptide. Cancer Chemotherapy and Pharmacology, 66(2):325–331.(PMID 20182728)
3. Bowne WB, Sookraj KA, Vishnevetsky M, Adler V, Sarafraz-Yazdi E, Lou S, Koenke J, Shteyler V, Ikram K, Harding M, Bluth MH, Ng M, Brandt-Rauf PW, Hannan R, Bradu S, Zenilman ME, Michl J, Pincus MR. (2008). The penetratin sequence in the anticancer PNC-28 peptide causes tumor cell necrosis rather than apoptosis of human pancreatic cancer cells. Annals of Surgical Oncology, 15(12):3588–3600.(PMID 18931881)

• Adipotide — same mechanism class
• Follistatin — same mechanism class
• FOXO4-DRI — same mechanism class
• Tesofensine — same mechanism class